LAMA84-r/Cre cells are derived from the human chronic myeloid leukemia cell line LAMA84-r by stably integration of a constitutive Cre recombinase stably expression construct. The LAMA84-r cell line is resistant to the tyrosine kinase inhibitor imatinib mesylate, and is paired to the LAMA84-s cell line which is sensitive to imatinib. The paired LAMA84-r and LAMA84-s cell lines are useful models of sensitivity and resistance to a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia. LAMA84-r/Cre cells stably express a nuclear localized Cre recombinase.